1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Xiamen Kingdomway Group Co. Class A

Xiamen Kingdomway Group Co. Class A

SSZSE:002626
18.65
CNY
+0.19
(+1.03%)
0.44EPS
29.05P/E
8.04BMarket Cap
Oct 27Next Earn
Xiamen Kingdomway Group Co. Class A
SZSE:002626
(Shenzhen Stock Exchange)

Recent

price

18.65

P/E

ratio

29.05

div

yld

4.39%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.25
1.27
1.16
1.15
1.47
2.14
2.83
3.39
4.64
5.17
5.74
5.91
4.91
5.05
5.31
5.54
5.67
Revenue per Share
0.33
0.29
0.17
0.18
0.34
0.2
0.51
0.77
1.11
0.73
1.57
1.29
0.42
0.45
0.56
0.56
0.45
Basic EPS, GAAP
0.19
-0.01
0.03
0.11
0.13
-1.14
0.6
0.66
1.3
1.2
1.18
0.82
0.87
0.66
0.26
0.54
- -
Free Cash Flow per Basic Share
0.04
0.09
0.1
0.09
0.15
0.18
0.08
0.23
0.44
0.9
0.65
0.67
0.66
0.26
0.24
0.45
0.82
Dividend per Share
0.86
2.12
2.2
2.29
2.47
2.53
3.51
4.03
4.9
4.72
5.56
6.44
5.99
6.44
7.02
7.31
6.89
Book Value per Share
0.81
2.09
2.17
2.26
2.44
1.05
2.07
2.68
2.85
3.24
3.94
4.98
4.7
5.14
5.57
6.1
5.68
Tangible Book Value per Share
429
455
581
584
572
563
588
616
619
617
611
612
613
615
611
607
606
Basic Weighted Avg Shares
536
578
676
670
838
1,204
1,663
2,085
2,873
3,192
3,504
3,616
3,009
3,103
3,240
3,365
3,435
Sales/Revenue/Turnover
32.43
28.54
16
16.01
24.43
12.11
21.31
29.41
33.77
28.3
34.42
30.03
16.02
11.53
14.87
15.82
14.86
Operating Margin (%)
25
27
34
38
50
72
88
83
98
120
112
179
207
209
205
209
- -
Depreciation Expense
142
132
102
102
195
113
300
474
687
451
959
789
257
277
342
340
275
Net Income, GAAP
15.14
16.52
13.72
14.07
15.78
16.13
17.36
17.62
17.73
25.82
16.78
16.04
21.11
17.46
21.83
15.13
15.79
Effective Tax Rate (%)
26.39
22.86
15.04
15.24
23.21
9.35
18.03
22.74
23.92
14.12
27.37
21.81
8.55
8.92
10.55
10.1
8
Profit Margin (%)
103
903
835
773
863
316
1,042
1,256
1,060
1,157
973
1,469
1,089
1,381
1,446
2,725
2,051
Working Capital
32
52
- -
- -
- -
289
380
334
734
776
681
896
467
653
715
1,693
1,523
LT Debt
369
1,221
1,269
1,317
1,421
1,541
2,180
2,491
3,021
2,955
3,492
4,027
3,665
3,936
4,318
4,496
4,308
Total Equity
31.89
14.62
7.38
7.31
13.71
5.27
10.64
15.57
18.31
10.27
20.84
15.77
4.97
6.14
7.16
5.07
4.43
Return on Invested Capital (%)
34.73
15.12
8.04
7.92
13.73
6.25
11.69
17.02
19.95
11.61
22.12
16.59
6.04
6.49
6.46
6.46
5.32
Return on Capital (%)
46.72
16.62
8.17
7.9
14.2
7.82
16.54
20.39
24.98
15.21
30.28
21.32
6.75
7.3
8.34
7.78
6.4
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
803
933
632
LT Borrowings
1,508
1,313
1,355
LT Finance Leases
185
171
168
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
610
610
610
Market Capitalization
12,022
10,698
8,039

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,024
3,816
3,191
Cash, Cash Equivalents & STI
2,560
2,379
1,712
Accounts Receivable, Net
370
388
429
Inventories
918
944
954
Total Current Liabilities
1,299
1,379
1,140
Payables & Accruals
- -
- -
- -
ST Debt
803
933
632
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.05%
5.51%
4.11%
Free Cash Flow
-5.3%
-0.12%
108.54%
Net Income, GAAP
29.31%
-10.93%
-0.61%
Sales/Revenue/Turnover
12%
-0.44%
3.87%
Total Cash Common Dividend
32.87%
4.31%
88.4%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
743
780
819
897
3,240
2025
827
901
- -
761
3,365
2026
813
960
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.1
0.15
0.2
0.56
2025
0.2
0.21
- -
-0.03
0.56
2026
0.11
0.17
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.21
0.02
- -
0.24
2025
0.02
0.41
- -
-0.02
0.45
2026
0.01
0.41
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Xiamen Kingdomway Group Company, founded in 1997 and headquartered in Xiamen, China, operates primarily in the pharmaceutical and biotechnology sectors specializing in nutritional and pharmaceutical raw materials. Its core product portfolio includes coenzyme Q10, DHA, ARA, vitamin A, vitamin D3, vitamin K2, nattokinase, PQQ, NMN, astaxanthin, and pharmaceutical raw materials such as praziquantel, alanyl glutamine, and olacetam. The company is one of the world's top manufacturers of vitamin A and vitamin D3, supplying products internationally and operating state-of-the-art manufacturing facilities certified to GMP and ISO standards. Recent major developments include the strategic acquisition of Viactiv, a US-based nutritional supplements firm, for $17.2 million in 2024, marking Kingdomway's significant expansion into the international over-the-counter (OTC) health product market. The company also reported robust financial performance in 2024, with revenue reaching approximately RMB 3.24 billion, a year-on-year increase of 4.43%, driven by growth in its vitamin and nutritional product segments. Additionally, Xiamen Kingdomway continues to invest heavily in research and development, with a focus on expanding its pipeline of biopharmaceutical products and enhancing manufacturing capabilities while emphasizing sustainability goals and international market expansion. Xiamen Kingdomway serves global markets with a strong presence in North America, Europe, and Asia, targeting pharmaceutical companies, health product distributors, and consumers seeking high-quality nutritional supplements and pharmaceutical ingredients. The company maintains a commitment to innovation and quality assurance as essential pillars for its business growth and competitive positioning.